Narmafotinib（AMP-945）是一种针对黏着斑激酶（FAK）的抑制剂。Narmafotinib在MDA-MB-231细胞中抑制了397Y-FAK的自磷酸化，并且表现出低细胞毒性（MDA-MB-231细胞）。

/

2~8℃避光保存，有效期3年。

[1] I.Street,M de Sylva,K.Lackovic,D.Ganame,G.Holloway,R.Anderson,G McArthur,A Natoli,J Doherty,H Falk,W Kersten,R Lessene,K Leuchowius,P Novello,H Yang,Y Bergman,M Camerino,S Charman,A Gregg,N Choi,R Foitzik,C Hemley,G Lunniss,M Nikac,S Walker,G Lovrecz,B Monahan,T Peat,C Robinson,C Scott,M Gorman,M Parker,I Holmes,M Devlin;Abstract LB-308:Combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer.Cancer Res 15 April 2012;72(8_Supplement):LB–308.https://doi.org/10.1158/1538-7445.AM2012-LB-308